John Holbein 5 months ago
Two new preprints on the efx of GLP-1s just dropped.
They use different samples, data, & designs.
But they come to the same conclusion on one point:
GLP-1s do not generate meaningful short- to medium-run reductions in non-GLP-1 medical spending, despite clear health benefits.